Access icon

Case Report January 12, 2023

Amisulpride-Induced High Elevation in Prolactin Levels

; ;

Prim Care Companion CNS Disord 2023;25(1):22cr03262

  1. Melmed S, Casanueva FF, Hoffman AR, et al; Endocrine Society. Diagnosis and treatment of hyperprolactinemia: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(2):273–288. PubMed CrossRef
  2. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239–245. PubMed CrossRef
  3. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand suppl. 1970;45;(S212):11–19. PubMed CrossRef
  4. Inder WJ, Castle D. Antipsychotic-induced hyperprolactinemia. Aust N Z J Psychiatry. 2011;45(10):830–837. PubMed CrossRef
  5. Zhu Y, Zhang C, Siafis S, et al. Prolactin levels influenced by antipsychotic drugs in schizophrenia: a systematic review and network meta-analysis. Schizophr Res. 2021;237:20–25. PubMed CrossRef
  6. Vilar L, Vilar CF, Lyra R, et al. Pitfalls in the diagnostic evaluation of hyperprolactinemia. Neuroendocrinology. 2019;109(1):7–19. PubMed CrossRef
  7. Andrade C. Low-dose amisulpride and elevation in serum prolactin. J Clin Psychiatry. 2013;74(6):e558–e560. PubMed CrossRef
  8. Kapur S, Langlois X, Vinken P, et al. The differential effects of atypical antipsychotics on prolactin elevation are explained by their differential blood-brain disposition: a pharmacological analysis in rats. J Pharmacol Exp Ther. 2002;302(3):1129–1134. PubMed CrossRef
  9. El-Mallakh RS, Watkins J. Prolactin elevations and the permeability glycoprotein. Prim Care Companion CNS Disord. 2019;21(3):18nr02412.https. PubMed CrossRef
  10. Holt RIG, Peveler RC. Antipsychotics and hyperprolactinaemia: mechanisms, consequences and management. Clin Endocrinol (Oxf). 2011;74(2):141–147. PubMed CrossRef
  11. Lee BH, Kang SG, Kim TW, et al. Hyperprolactinemia induced by low-dosage amisulpride in Korean psychiatric patients. Psychiatry Clin Neurosci. 2012;66(1):69–73. PubMed CrossRef
  12. Raj R, Sidhu BS. Hyperprolactinemia with amisulpride. Indian J Psychiatry. 2008;50(1):54–56. PubMed CrossRef
  13. Kopecek M, Bares M, Svarc J, et al. Hyperprolactinemia after low dose of amisulpride. Neuroendocrinol Lett. 2004;25(6):419–422. PubMed
  14. Glatard A, Guidi M, Delacrétaz A, et al. Amisulpride: real-world evidence of dose adaptation and effect on prolactin concentrations and body weight gain by pharmacokinetic/pharmacodynamic analyses. Clin Pharmacokinet. 2020;59(3):371–382. PubMed CrossRef
  15. Zhang L, Qi H, Xie YY, et al. Efficacy and safety of adjunctive aripiprazole, metformin, and paeoniae-glycyrrhiza decoction for antipsychotic-induced hyperprolactinemia: a network meta-analysis of randomized controlled trials. Front Psychiatry. 2021;12:728204. PubMed CrossRef
  16. Chen CK, Huang YS, Ree SC, et al. Differential add-on effects of aripiprazole in resolving hyperprolactinemia induced by risperidone in comparison to benzamide antipsychotics. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34(8):1495–1499. PubMed CrossRef